{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T13:45:56Z","timestamp":1790084756959,"version":"4.0.1"},"reference-count":91,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T00:00:00Z","timestamp":1786320000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,9,22]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Patients with Fontan circulation represent a pharmacologically distinct population in whom the haemodynamic consequences of single-ventricle physiology alter every phase of drug disposition in ways that current prescribing practice systematically fails to account for. Fontan-associated liver disease suppresses hepatic CYP enzyme activity and reduces first-pass metabolism, increasing bioavailability and systemic exposure of drugs. Hypoalbuminaemia from protein-losing enteropathy elevates the free fraction of highly protein-bound agents, rendering standard total drug concentration targets unreliable. Reduced cardiac output contracts the volume of distribution of hydrophilic drugs and diminishes renal perfusion, while creatinine-based glomerular filtration rate equations systematically overestimate true renal function due to reduced skeletal muscle mass, leading to inadequate dose reduction for renally cleared agents. These disturbances are predicted to affect the pharmacokinetics of every major cardiovascular drug class prescribed in this population, including anticoagulants, antiarrhythmics, neurohormonal antagonists, and pulmonary vasodilators, although direct Fontan-specific pharmacokinetic data remain scarce and confirm these effects for only a minority of agents, with dosing largely extrapolated from non-congenital populations. This review examines the mechanistic basis of pharmacokinetic alterations across drug disposition, evaluate available drug-class evidence, and outlines a research agenda including physiologically based pharmacokinetic modelling, registry-embedded studies, and dedicated inclusion of Fontan patients in future trials.<\/jats:p>","DOI":"10.1093\/ehjcvp\/pvag058","type":"journal-article","created":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T11:11:34Z","timestamp":1786101094000},"page":"480-489","source":"Crossref","is-referenced-by-count":1,"title":["Pharmacokinetics in the Fontan circulation: a multi-organ puzzle"],"prefix":"10.1093","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0736-4942","authenticated-orcid":false,"given":"Panayotis K","family":"Vlachakis","sequence":"first","affiliation":[{"name":"First Department of Cardiology, Hippokration General Hospital of Athens, National and Kapodistrian University of Athens , 114 Vasilissis Sophias, Athens 11527 ,","place":["Greece"]},{"name":"Unit of Structural Heart Diseases, First Department of Cardiology, Medical School, Hippocration General Hospital of Athens, National and Kapodistrian University of Athens , 114 Vasilissis Sophias, Athens 11527 ,","place":["Greece"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0016-3788","authenticated-orcid":false,"given":"Maria","family":"Drakopoulou","sequence":"additional","affiliation":[{"name":"First Department of Cardiology, Hippokration General Hospital of Athens, National and Kapodistrian University of Athens , 114 Vasilissis Sophias, Athens 11527 ,","place":["Greece"]},{"name":"Unit of Structural Heart Diseases, First Department of Cardiology, Medical School, Hippocration General Hospital of Athens, National and Kapodistrian University of Athens , 114 Vasilissis Sophias, Athens 11527 ,","place":["Greece"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9260-6306","authenticated-orcid":false,"given":"Panagiotis","family":"Theofilis","sequence":"additional","affiliation":[{"name":"First Department of Cardiology, Hippokration General Hospital of Athens, National and Kapodistrian University of Athens , 114 Vasilissis Sophias, Athens 11527 ,","place":["Greece"]},{"name":"Unit of Structural Heart Diseases, First Department of Cardiology, Medical School, Hippocration General Hospital of Athens, National and Kapodistrian University of Athens , 114 Vasilissis Sophias, Athens 11527 ,","place":["Greece"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3561-5713","authenticated-orcid":false,"given":"Paschalis","family":"Karakasis","sequence":"additional","affiliation":[{"name":"Second Department of Cardiology, Hippokration General Hospital, Aristotle University of Thessaloniki , Thessaloniki 54642 ,","place":["Greece"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6992-2906","authenticated-orcid":false,"given":"Ioannis","family":"Leontsinis","sequence":"additional","affiliation":[{"name":"First Department of Cardiology, Hippokration General Hospital of Athens, National and Kapodistrian University of Athens , 114 Vasilissis Sophias, Athens 11527 ,","place":["Greece"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7636-6725","authenticated-orcid":false,"given":"Konstantinos","family":"Tsioufis","sequence":"additional","affiliation":[{"name":"First Department of Cardiology, Hippokration General Hospital of Athens, National and Kapodistrian University of Athens , 114 Vasilissis Sophias, Athens 11527 ,","place":["Greece"]},{"name":"Unit of Structural Heart Diseases, First Department of Cardiology, Medical School, Hippocration General Hospital of Athens, National and Kapodistrian University of Athens , 114 Vasilissis Sophias, Athens 11527 ,","place":["Greece"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2946-344X","authenticated-orcid":false,"given":"Konstantinos","family":"Toutouzas","sequence":"additional","affiliation":[{"name":"First Department of Cardiology, Hippokration General Hospital of Athens, National and Kapodistrian University of Athens , 114 Vasilissis Sophias, Athens 11527 ,","place":["Greece"]},{"name":"Unit of Structural Heart Diseases, First Department of Cardiology, Medical School, Hippocration General Hospital of Athens, National and Kapodistrian University of Athens , 114 Vasilissis Sophias, Athens 11527 ,","place":["Greece"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,8,10]]},"reference":[{"key":"2026092119571002200_pvag058-B1","doi-asserted-by":"publisher","first-page":"2241","DOI":"10.1016\/j.jacc.2011.08.025","article-title":"Birth prevalence of congenital heart disease worldwide: a systematic review and meta-analysis","volume":"58","author":"van der Linde","year":"2011","journal-title":"J Am Coll Cardiol"},{"key":"2026092119571002200_pvag058-B2","doi-asserted-by":"publisher","first-page":"e234","DOI":"10.1161\/CIR.0000000000000696","article-title":"Evaluation and management of the child and adult with Fontan circulation: a scientific statement from the American Heart Association","volume":"140","author":"Rychik","year":"2019","journal-title":"Circulation"},{"key":"2026092119571002200_pvag058-B3","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.ijcard.2016.05.035","article-title":"The Fontan epidemic: population projections from the Australia and New Zealand Fontan Registry","volume":"219","author":"Schilling","year":"2016","journal-title":"Int J Cardiol"},{"key":"2026092119571002200_pvag058-B4","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1161\/CIRCULATIONAHA.120.045597","article-title":"Fontan-associated liver disease: screening, management, and transplant considerations","volume":"142","author":"Emamaullee","year":"2020","journal-title":"Circulation"},{"key":"2026092119571002200_pvag058-B5","doi-asserted-by":"publisher","first-page":"1700","DOI":"10.1016\/j.jacc.2015.07.065","article-title":"40-Year Follow-up after the Fontan operation: long-term outcomes of 1,052 patients","volume":"66","author":"Pundi","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"2026092119571002200_pvag058-B6","doi-asserted-by":"publisher","DOI":"10.1007\/s00246-025-04145-4","article-title":"Survival by heart failure phenotype in a Fontan surveillance population, 2010-2023","author":"Ivey","year":"2026","journal-title":"Pediatr Cardiol"},{"key":"2026092119571002200_pvag058-B7","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1016\/j.jacc.2025.09.006","article-title":"2025 ACC\/AHA\/HRS\/ISACHD\/SCAI guideline for the management of adults with congenital heart disease: a report of the American College of Cardiology\/American Heart Association Joint Committee on clinical practice guidelines","volume":"87","author":"Gurvitz","year":"2026","journal-title":"J Am Coll Cardiol"},{"key":"2026092119571002200_pvag058-B8","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1093\/eurheartj\/ehaa554","article-title":"2020 ESC guidelines for the management of adult congenital heart disease","volume":"42","author":"Baumgartner","year":"2021","journal-title":"Eur Heart J"},{"key":"2026092119571002200_pvag058-B9","doi-asserted-by":"publisher","DOI":"10.4070\/kcj.2025.0455","article-title":"2025 clinical practice guidelines for the management of Fontan patients in Korea: a consensus statement with graded recommendations by the committee for clinical practice guidelines on Fontan patients","author":"Cho","year":"2026","journal-title":"Korean Circ J"},{"key":"2026092119571002200_pvag058-B10","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1136\/heartjnl-2015-307467","article-title":"The Fontan circulation after 45 years: update in physiology","volume":"102","author":"Gewillig","year":"2016","journal-title":"Heart"},{"key":"2026092119571002200_pvag058-B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacadv.2024.101399","article-title":"Deterioration in renal function in patients with a Fontan circulation and association with mortality","volume":"3","author":"van Hassel","year":"2024","journal-title":"JACC Adv"},{"key":"2026092119571002200_pvag058-B12","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1510\/icvts.2009.218594","article-title":"The Fontan circulation: who controls cardiac output?","volume":"10","author":"Gewillig","year":"2010","journal-title":"Interact Cardiovasc Thorac Surg"},{"key":"2026092119571002200_pvag058-B13","doi-asserted-by":"publisher","DOI":"10.3389\/fped.2023.1100514","article-title":"Fontan-associated liver disease: diagnosis, surveillance, and management","volume":"11","author":"de Lange","year":"2023","journal-title":"Front Pediatr"},{"key":"2026092119571002200_pvag058-B14","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1016\/j.amjcard.2015.11.014","article-title":"Liver disease in patients after the Fontan operation","volume":"117","author":"Pundi","year":"2016","journal-title":"Am J Cardiol"},{"key":"2026092119571002200_pvag058-B15","doi-asserted-by":"publisher","first-page":"3173","DOI":"10.1016\/j.jacc.2017.10.045","article-title":"Fontan-associated liver disease: proceedings from the American College of Cardiology Stakeholders Meeting, October 1 to 2, 2015, Washington DC","volume":"70","author":"Daniels","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"2026092119571002200_pvag058-B16","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1111\/bcp.15990","article-title":"Effect of changes in metabolic enzymes and transporters on drug metabolism in the context of liver disease: impact on pharmacokinetics and drug-drug interactions","volume":"90","author":"Armani","year":"2024","journal-title":"Br J Clin Pharmacol"},{"key":"2026092119571002200_pvag058-B17","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.124.039201","article-title":"Comprehensive multiomic analysis reveals metabolic reprogramming underlying human Fontan-associated liver disease","volume":"14","author":"Sule","year":"2025","journal-title":"J Am Heart Assoc"},{"key":"2026092119571002200_pvag058-B18","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.humpath.2016.07.006","article-title":"Prevalence and characterization of fibrosis in surveillance liver biopsies of patients with Fontan circulation","volume":"57","author":"Surrey","year":"2016","journal-title":"Hum Pathol"},{"key":"2026092119571002200_pvag058-B19","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1111\/hepr.13627","article-title":"Assessing liver stiffness with conventional cut-off values overestimates liver fibrosis staging in patients who received the Fontan procedure","volume":"51","author":"Cho","year":"2021","journal-title":"Hepatol Res"},{"key":"2026092119571002200_pvag058-B20","doi-asserted-by":"publisher","first-page":"1338","DOI":"10.1016\/j.cjca.2023.04.019","article-title":"Determinants of advanced liver fibrosis in adult patients after Fontan palliation: usefulness of ultrasound transient elastography","volume":"39","author":"B\u00fctikofer","year":"2023","journal-title":"Can J Cardiol"},{"key":"2026092119571002200_pvag058-B21","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1016\/j.cjca.2022.03.011","article-title":"Plastic bronchitis and protein-losing enteropathy in the Fontan patient: evolving understanding and emerging therapies","volume":"38","author":"Mackie","year":"2022","journal-title":"Can J Cardiol"},{"key":"2026092119571002200_pvag058-B22","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2025.1546465","article-title":"Effect of hypoalbuminemia on drug pharmacokinetics","volume":"16","author":"Idasiak-Piechocka","year":"2025","journal-title":"Front Pharmacol"},{"key":"2026092119571002200_pvag058-B23","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1016\/j.ijcha.2019.02.007","article-title":"Bound to bleed: how altered albumin binding may dictate warfarin treatment outcome","volume":"22","author":"Fender","year":"2019","journal-title":"Int J Cardiol Heart Vasc"},{"key":"2026092119571002200_pvag058-B24","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s40885-017-0083-z","article-title":"Severe carvedilol toxicity without overdose - caution in cirrhosis","volume":"23","author":"Maharaj","year":"2017","journal-title":"Clin Hypertens"},{"key":"2026092119571002200_pvag058-B25","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1002\/j.1552-4604.1997.tb04783.x","article-title":"Protein binding in plasma of valsartan, a new angiotensin II receptor antagonist","volume":"37","author":"Colussi","year":"1997","journal-title":"J Clin Pharmacol"},{"key":"2026092119571002200_pvag058-B26","doi-asserted-by":"publisher","first-page":"515","DOI":"10.3390\/antibiotics12030515","article-title":"Hypoalbuminemia and pharmacokinetics: when the misunderstanding of a fundamental concept leads to repeated errors over decades","volume":"12","author":"Gandia","year":"2023","journal-title":"Antibiotics (Basel)"},{"key":"2026092119571002200_pvag058-B27","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.122.029130","article-title":"Associations between characteristics of individuals with Fontan circulation with blood and urine biomarkers of kidney injury and dysfunction","volume":"12","author":"Katz","year":"2023","journal-title":"J Am Heart Assoc"},{"key":"2026092119571002200_pvag058-B28","doi-asserted-by":"publisher","DOI":"10.1002\/cph4.70116","article-title":"Phenotyping of Fontan-associated renal physiology and disease","volume":"16","author":"van Hassel","year":"2026","journal-title":"Compr Physiol"},{"key":"2026092119571002200_pvag058-B29","doi-asserted-by":"publisher","first-page":"1530","DOI":"10.1136\/heartjnl-2013-304249","article-title":"Skeletal muscle abnormalities and exercise capacity in adults with a Fontan circulation","volume":"99","author":"Cordina","year":"2013","journal-title":"Heart"},{"key":"2026092119571002200_pvag058-B30","doi-asserted-by":"publisher","first-page":"4309","DOI":"10.1007\/s00431-023-05100-2","article-title":"Body composition in patients with Fontan physiology: a systematic review","volume":"182","author":"van den Berg","year":"2023","journal-title":"Eur J Pediatr"},{"key":"2026092119571002200_pvag058-B31","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1111\/chd.12746","article-title":"Creatinine-based estimation of glomerular filtration rate in patients with a Fontan circulation","volume":"14","author":"Wilson","year":"2019","journal-title":"Congenit Heart Dis"},{"key":"2026092119571002200_pvag058-B32","first-page":"486","article-title":"Variations of sotalol kinetics in renal insufficiency","volume":"27","author":"Dumas","year":"1989","journal-title":"Int J Clin Pharmacol Ther Toxicol"},{"key":"2026092119571002200_pvag058-B33","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1111\/j.1365-2125.2007.02899.x","article-title":"The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects","volume":"64","author":"Stangier","year":"2007","journal-title":"Br J Clin Pharmacol"},{"key":"2026092119571002200_pvag058-B34","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2165\/00003088-197702010-00001","article-title":"Clinical pharmacokinetics of digoxin","volume":"2","author":"Iisalo","year":"1977","journal-title":"Clin Pharmacokinet"},{"key":"2026092119571002200_pvag058-B35","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1159\/000176468","article-title":"Comparative pharmacokinetics and pharmacodynamics of loop diuretics in renal failure","volume":"84","author":"Risler","year":"1994","journal-title":"Cardiology"},{"key":"2026092119571002200_pvag058-B36","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1067\/mtc.2001.112527","article-title":"Subdiaphragmatic venous hemodynamics in the Fontan circulation","volume":"121","author":"Hsia","year":"2001","journal-title":"J Thorac Cardiovasc Surg"},{"key":"2026092119571002200_pvag058-B37","doi-asserted-by":"publisher","first-page":"314","DOI":"10.7326\/0003-4819-102-3-314","article-title":"Furosemide absorption altered in decompensated congestive heart failure","volume":"102","author":"Vasko","year":"1985","journal-title":"Ann Intern Med"},{"key":"2026092119571002200_pvag058-B38","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1111\/j.1527-5299.2003.02399.x","article-title":"Pharmacotherapy in congestive heart failure: drug absorption in the management of congestive heart failure: loop diuretics","volume":"9","author":"Sica","year":"2003","journal-title":"Congest Heart Fail"},{"key":"2026092119571002200_pvag058-B39","doi-asserted-by":"publisher","first-page":"S142","DOI":"10.1097\/00005344-199219001-00028","article-title":"Disposition of carvedilol enantiomers in patients with liver cirrhosis: evidence for disappearance of stereoselective first-pass extraction","volume":"19","author":"Neugebauer","year":"1992","journal-title":"J Cardiovasc Pharmacol"},{"key":"2026092119571002200_pvag058-B40","doi-asserted-by":"publisher","first-page":"335","DOI":"10.2165\/00003088-199426050-00002","article-title":"Clinical pharmacokinetics and pharmacodynamics of carvedilol","volume":"26","author":"Morgan","year":"1994","journal-title":"Clin Pharmacokinet"},{"key":"2026092119571002200_pvag058-B41","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1002\/jcph.1966","article-title":"Dosing regimen prediction and confirmation with rivaroxaban for thromboprophylaxis in children after the Fontan procedure: insights from the phase III UNIVERSE study","volume":"62","author":"Zhu","year":"2022","journal-title":"J Clin Pharmacol"},{"key":"2026092119571002200_pvag058-B42","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.pharmthera.2012.12.007","article-title":"Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation","volume":"138","author":"Zanger","year":"2013","journal-title":"Pharmacol Ther"},{"key":"2026092119571002200_pvag058-B43","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1002\/cpt1975184377","article-title":"Commentary: a physiological approach to hepatic drug clearance","volume":"18","author":"Wilkinson","year":"1975","journal-title":"Clin Pharmacol Ther"},{"key":"2026092119571002200_pvag058-B44","doi-asserted-by":"publisher","first-page":"135","DOI":"10.2165\/00003088-197601020-00005","article-title":"Altered hepatic blood flow and drug disposition","volume":"1","author":"Nies","year":"1976","journal-title":"Clin Pharmacokinet"},{"key":"2026092119571002200_pvag058-B45","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1007\/s00246-021-02565-6","article-title":"Carvedilol does not improve exercise performance in Fontan patients: results of a crossover trial","volume":"42","author":"Butts","year":"2021","journal-title":"Pediatr Cardiol"},{"key":"2026092119571002200_pvag058-B46","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1067\/mpd.2001.113045","article-title":"Carvedilol as therapy in pediatric heart failure: an initial multicenter experience","volume":"138","author":"Bruns","year":"2001","journal-title":"J Pediatr"},{"key":"2026092119571002200_pvag058-B47","volume-title":"Medical Genetics Summaries","author":"Dean","year":"2012"},{"key":"2026092119571002200_pvag058-B48","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1046\/j.1365-2125.2000.00134.x","article-title":"Inhibitory effects of amiodarone and its N-deethylated metabolite on human cytochrome P450 activities: prediction of in vivo drug interactions","volume":"49","author":"Ohyama","year":"2000","journal-title":"Br J Clin Pharmacol"},{"key":"2026092119571002200_pvag058-B49","doi-asserted-by":"publisher","first-page":"1661","DOI":"10.1124\/dmd.115.065623","article-title":"P450-based drug-drug interactions of amiodarone and its metabolites: diversity of inhibitory mechanisms","volume":"43","author":"McDonald","year":"2015","journal-title":"Drug Metab Dispos"},{"key":"2026092119571002200_pvag058-B50","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1038\/clpt.2011.283","article-title":"Warfarin-amiodarone drug-drug interactions: determination of [I](u)\/K(I,u) for amiodarone and its plasma metabolites","volume":"91","author":"McDonald","year":"2012","journal-title":"Clin Pharmacol Ther"},{"key":"2026092119571002200_pvag058-B51","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1111\/chd.12657","article-title":"Adverse effects of amiodarone therapy in adults with congenital heart disease","volume":"13","author":"Moore","year":"2018","journal-title":"Congenit Heart Dis"},{"key":"2026092119571002200_pvag058-B52","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1136\/heartjnl-2020-317378","article-title":"Role of amiodarone in the management of atrial arrhythmias in adult Fontan patients","volume":"107","author":"Kawada","year":"2021","journal-title":"Heart"},{"key":"2026092119571002200_pvag058-B53","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1016\/j.jacc.2020.05.042","article-title":"Long-term kidney function after the Fontan operation: JACC review topic of the week","volume":"76","author":"Zafar","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"2026092119571002200_pvag058-B54","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.ahj.2019.04.018","article-title":"Creatinine versus cystatin C to estimate glomerular filtration rate in adults with congenital heart disease: results of the Boston Adult Congenital Heart Disease Biobank","volume":"214","author":"Opotowsky","year":"2019","journal-title":"Am Heart J"},{"key":"2026092119571002200_pvag058-B55","doi-asserted-by":"publisher","first-page":"F867","DOI":"10.1152\/ajprenal.00528.2007","article-title":"Overlapping in vitro and in vivo specificities of the organic anion transporters OAT1 and OAT3 for loop and thiazide diuretics","volume":"294","author":"Vallon","year":"2008","journal-title":"Am J Physiol Renal Physiol"},{"key":"2026092119571002200_pvag058-B56","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.133817","article-title":"Gut-derived uremic toxin handling in vivo requires OAT-mediated tubular secretion in chronic kidney disease","volume":"5","author":"Bush","year":"2020","journal-title":"JCI Insight"},{"key":"2026092119571002200_pvag058-B57","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1016\/j.jacc.2022.10.037","article-title":"Thromboprophylaxis in patients with Fontan circulation","volume":"81","author":"Van den Eynde","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"2026092119571002200_pvag058-B58","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.125.045788","article-title":"Long-term outcomes of antithrombotic treatment in a cohort of 864 patients with Fontan circulation","volume":"15","author":"Ozturk","year":"2026","journal-title":"J Am Heart Assoc"},{"key":"2026092119571002200_pvag058-B59","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/S0009-9236(98)90160-6","article-title":"Protein binding of aspirin and salicylate measured by in vivo ultrafiltration","volume":"63","author":"Ghahramani","year":"1998","journal-title":"Clin Pharmacol Ther"},{"key":"2026092119571002200_pvag058-B60","doi-asserted-by":"publisher","first-page":"e50","DOI":"10.1161\/CIR.0000000000000458","article-title":"Management of pregnancy in patients with complex congenital heart disease: a scientific statement for healthcare professionals from the American Heart Association","volume":"135","author":"Canobbio","year":"2017","journal-title":"Circulation"},{"key":"2026092119571002200_pvag058-B61","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1016\/j.cjca.2022.01.028","article-title":"Coagulation and anticoagulation in Fontan patients","volume":"38","author":"Heidendael","year":"2022","journal-title":"Can J Cardiol"},{"key":"2026092119571002200_pvag058-B62","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1016\/j.jacc.2012.08.1023","article-title":"Factors associated with thrombotic complications after the Fontan procedure: a secondary analysis of a multicenter, randomized trial of primary thromboprophylaxis for 2 years after the Fontan procedure","volume":"61","author":"McCrindle","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"2026092119571002200_pvag058-B63","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1093\/ejcts\/ezw159","article-title":"No difference between aspirin and warfarin after extracardiac Fontan in a propensity score analysis of 475 patients","volume":"50","author":"Iyengar","year":"2016","journal-title":"Eur J Cardiothorac Surg"},{"key":"2026092119571002200_pvag058-B64","doi-asserted-by":"publisher","first-page":"2296","DOI":"10.1016\/j.jacc.2023.10.010","article-title":"Apixaban for prevention of thromboembolism in pediatric heart disease","volume":"82","author":"Payne","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"2026092119571002200_pvag058-B65","doi-asserted-by":"publisher","first-page":"2283","DOI":"10.1007\/s00246-024-03641-3","article-title":"Real-world use and outcomes of apixaban for early post-surgical Fontan thromboprophylaxis","volume":"46","author":"Adkins","year":"2025","journal-title":"Pediatr Cardiol"},{"key":"2026092119571002200_pvag058-B66","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.cardfail.2025.05.020","article-title":"Efficacy of heart failure medications in Fontan circulation: a systematic review of evidence and gaps in pharmacological strategy","volume":"32","author":"Abdulkarim","year":"2026","journal-title":"J Card Fail"},{"key":"2026092119571002200_pvag058-B67","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1161\/01.cir.96.5.1507","article-title":"Enalapril does not enhance exercise capacity in patients after Fontan procedure","volume":"96","author":"Kouatli","year":"1997","journal-title":"Circulation"},{"key":"2026092119571002200_pvag058-B68","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.amjcard.2021.10.013","article-title":"3-Month enalapril treatment in pediatric fontan patients with moderate to good systolic ventricular function","volume":"163","author":"Harteveld","year":"2022","journal-title":"Am J Cardiol"},{"key":"2026092119571002200_pvag058-B69","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1017\/S1047951121002791","article-title":"Adolescents and adults with Fontan circulation: insights from the PREpArE-fontan registry","volume":"32","author":"S\u00f8ndergaard","year":"2022","journal-title":"Cardiol Young"},{"key":"2026092119571002200_pvag058-B70","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.1253\/circj.cj-10-0845","article-title":"Effect of carvedilol on heart failure in patients with a functionally univentricular heart","volume":"75","author":"Ishibashi","year":"2011","journal-title":"Circ J"},{"key":"2026092119571002200_pvag058-B71","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1001\/jama.298.10.1171","article-title":"Carvedilol for children and adolescents with heart failure: a randomized controlled trial","volume":"298","author":"Shaddy","year":"2007","journal-title":"JAMA"},{"key":"2026092119571002200_pvag058-B72","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhlto.2025.100426","article-title":"Heart failure in congenital heart disease-how to manage the Fontan patient","volume":"11","author":"Gada","year":"2026","journal-title":"JHLT Open"},{"key":"2026092119571002200_pvag058-B73","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1056\/NEJMoa1409077","article-title":"Angiotensin-neprilysin inhibition versus enalapril in heart failure","volume":"371","author":"McMurray","year":"2014","journal-title":"N Engl J Med"},{"key":"2026092119571002200_pvag058-B74","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaccas.2024.102395","article-title":"Protein-losing enteropathy in the failing Fontan: treatment with angiotensin receptor neprilysin inhibitor","volume":"29","author":"Sanders","year":"2024","journal-title":"JACC Case Rep"},{"key":"2026092119571002200_pvag058-B75","doi-asserted-by":"publisher","first-page":"1581","DOI":"10.1007\/s00246-025-03938-x","article-title":"Single-center experience with sacubitril\/valsartan in patients with congenital heart disease","volume":"47","author":"Konduri","year":"2026","journal-title":"Pediatr Cardiol"},{"key":"2026092119571002200_pvag058-B76","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.ijcard.2019.06.031","article-title":"Sacubitril\/valsartan for heart failure in adults with complex congenital heart disease","volume":"300","author":"Maurer","year":"2020","journal-title":"Int J Cardiol"},{"key":"2026092119571002200_pvag058-B77","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcchd.2021.100268","article-title":"Sacubitril\/valsartan for heart failure in patients with complex adult congenital heart disease \u2013 experience from a tertiary centre in Singapore","volume":"6","author":"Yan","year":"2021","journal-title":"Int J Cardiol Congenit Heart Dis"},{"key":"2026092119571002200_pvag058-B78","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcchd.2021.100096","article-title":"The protocol and rationale for the efficacy aNd ToleRability of sacUbitril-valSarTan in adult congenital heart disease patients with heart failure (ENTRUST ACHD HF) registry","volume":"3","author":"Appadurai","year":"2021","journal-title":"Int J Cardiol Congenit Heart Dis"},{"key":"2026092119571002200_pvag058-B79","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1002\/ejhf.3024","article-title":"2023 focused update of the 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: developed by the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) with the special contribution of the Heart Failure Association (HFA) of the ESC","volume":"26","author":"Authors\/Task Force Members","year":"2024","journal-title":"Eur J Heart Fail"},{"key":"2026092119571002200_pvag058-B80","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1007\/s00246-023-03332-5","article-title":"Experience with SGLT2 inhibitors in patients with single ventricle congenital heart disease and Fontan circulatory failure","volume":"46","author":"Konduri","year":"2025","journal-title":"Pediatr Cardiol"},{"key":"2026092119571002200_pvag058-B81","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcchd.2025.100603","article-title":"Echocardiographic effects of sodium-glucose cotransporter 2 inhibitors in single ventricle circulatory failure","volume":"21","author":"Neijenhuis","year":"2025","journal-title":"Int J Cardiol Congenit Heart Dis"},{"key":"2026092119571002200_pvag058-B82","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2026.1771868","article-title":"Real-world experience with sodium-glucose cotransporter 2 inhibitors in adults with Fontan circulatory failure","volume":"13","author":"Neijenhuis","year":"2026","journal-title":"Front Cardiovasc Med"},{"key":"2026092119571002200_pvag058-B83","doi-asserted-by":"publisher","DOI":"10.3389\/fped.2025.1506690","article-title":"Review of rhythm disturbances in patient after Fontan completion: epidemiology, management, and surveillance","volume":"13","author":"Wall","year":"2025","journal-title":"Front Pediatr"},{"key":"2026092119571002200_pvag058-B84","doi-asserted-by":"publisher","first-page":"1998","DOI":"10.1253\/circj.cj-08-0194","article-title":"Efficacy and safety of sotalol for refractory tachyarrhythmias in congenital heart disease","volume":"72","author":"Miyazaki","year":"2008","journal-title":"Circ J"},{"key":"2026092119571002200_pvag058-B85","doi-asserted-by":"publisher","DOI":"10.1093\/europace\/euaf076","article-title":"Practical compendium of antiarrhythmic drugs: a clinical consensus statement of the European Heart Rhythm Association of the European Society of Cardiology","volume":"27","author":"Merino","year":"2025","journal-title":"Europace"},{"key":"2026092119571002200_pvag058-B86","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.21037\/atm-21-3188","article-title":"Pharmacokinetics of treprostinil in children with functional single-ventricle pulmonary arterial hypertension: a randomized controlled trial","volume":"9","author":"Chen","year":"2021","journal-title":"Ann Transl Med"},{"key":"2026092119571002200_pvag058-B87","doi-asserted-by":"publisher","first-page":"e795","DOI":"10.1097\/PCC.0000000000002410","article-title":"A randomized, controlled pharmacokinetic and pharmacodynamics trial of ambrisentan after Fontan surgery","volume":"21","author":"Hill","year":"2020","journal-title":"Pediatr Crit Care Med"},{"key":"2026092119571002200_pvag058-B88","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1002\/psp4.12688","article-title":"Population pharmacokinetic analysis of rivaroxaban in children and comparison toprospective physiologically-based pharmacokinetic predictions","volume":"10","author":"Willmann","year":"2021","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"2026092119571002200_pvag058-B89","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1111\/apt.16489","article-title":"Review article: time to revisit Child-Pugh score as the basis for predicting drug clearance in hepatic impairment","volume":"54","author":"El-Khateeb","year":"2021","journal-title":"Aliment Pharmacol Ther"},{"key":"2026092119571002200_pvag058-B90","doi-asserted-by":"publisher","DOI":"10.1002\/psp4.70215","article-title":"Comprehensive pathophysiology repository for PBPK modeling in liver cirrhosis: quantifying continuous disease progression and population variability","volume":"15","author":"Schneider","year":"2026","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"2026092119571002200_pvag058-B91","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.122.009816","article-title":"Baseline characteristics of pediatric patients with heart failure due to systemic left ventricular systolic dysfunction in the PANORAMA-HF trial","volume":"16","author":"Shaddy","year":"2023","journal-title":"Circ Heart Fail"}],"container-title":["European Heart Journal - Cardiovascular Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ehjcvp\/advance-article-pdf\/doi\/10.1093\/ehjcvp\/pvag058\/70602013\/pvag058.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ehjcvp\/article-pdf\/12\/6\/480\/70602013\/pvag058.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ehjcvp\/article-pdf\/12\/6\/480\/70602013\/pvag058.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T23:57:21Z","timestamp":1790035041000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ehjcvp\/article\/12\/6\/480\/8758101"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,10]]},"references-count":91,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2026,8,10]]},"published-print":{"date-parts":[[2026,9,22]]}},"URL":"https:\/\/doi.org\/10.1093\/ehjcvp\/pvag058","relation":{},"ISSN":["2055-6837","2055-6845"],"issn-type":[{"value":"2055-6837","type":"print"},{"value":"2055-6845","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,9]]},"published":{"date-parts":[[2026,8,10]]}}}